London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Long term follow up of INTACS™ in keratoconus

Poster Details

First Author: O.Ucakhan TURKEY

Co Author(s):    B. Bayraktutar              

Abstract Details

Purpose:

To evaluate the safety and efficacy of INTACS implantation in keratoconic eyes in long-term follow-up.

Setting:

Department of Ophthalmology, Ankara University School of Medicine, Ankara, Turkey

Methods:

Fifty-eight eyes of 39 keratoconus patients with contact lens intolerance were included into this prospective study. The uncorrected (UDVA)- and corrected(CDVA)-distance visual acuities, manifest refraction, biomicroscopy, corneal topography, and contrast sensitivity findings were noted before INTACS implantation and at postoperative week-1, months-1,3,6,12 and yearly thereafter.

Results:

The mean age of the patients was 29.5 ± 6.1 years and the mean follow-up was 32.2 ± 11.7 months. The mean preoperative UDVA and CDVA were 0.8 ± 0.4 logMAR, and 0.25 ± 0.23 logMAR, respectively, and improved to 0.42 ± 0.32 logMAR and 0.12 ± 0.18 logMAR at the last postoperative examination. The mean keratometry readings improved from 48.5 ± 4.5 D to 47 ± 11.8 D, and the mean manifest refraction spherical equivalent improved from -5.4 ± 4.4 D to -2.8 ± 2.9 D. Following INTACS implantation, contrast sensitivity at low and medium spatial frequencies improved significantly.

Conclusions:

In keratoconic eyes with contact lens intolerance, INTACS implantation safely and effectively improved vision, refractive error and the topography findings. The visual and refractive outcome seemed to be stable in long-term follow-up.

Financial Disclosure:

NONE

Back to Poster listing